Medtronic Financial Statements (MDT) |
||||||||||
Medtronicsmart-lab.ru | % | 2022 | 2022 | 2023 | 2023 | 2024 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 29.04.2022 | 23.06.2022 | 30.04.2023 | 22.06.2023 | 30.04.2024 | 23.05.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 31 686 | 31 686 | 31 227 | 31 227 | 24 662 | ||||
Operating Income, bln rub | 5 752 | 5 752 | 5 485 | 5 485 | 4 632 | |||||
EBITDA, bln rub | ? | 8 755 | 8 932 | 9 042 | 9 042 | 6 216 | ||||
Net profit, bln rub | ? | 5 039 | 5 039 | 3 758 | 3 758 | 2 885 | ||||
OCF, bln rub | ? | 7 346 | 7 346 | 6 039 | 6 039 | 3 146 | ||||
CAPEX, bln rub | ? | 1 368 | 1 368 | 1 459 | 1 459 | 807.0 | ||||
FCF, bln rub | ? | 5 978 | 5 978 | 4 580 | 4 580 | 2 339 | ||||
Dividend payout, bln rub | 3 383 | 3 383 | 3 616 | 3 616 | 1 835 | |||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
Dividend payout ratio, % | 67.1% | 67.1% | 96.2% | 96.2% | 63.6% | |||||
OPEX, bln rub | 13 038 | 15 633 | 14 678 | 14 678 | 10 971 | |||||
Cost of production, bln rub | 10 145 | 10 145 | 10 719 | 10 719 | 8 498 | |||||
R&D, bln rub | 2 746 | 2 746 | 2 696 | 2 696 | 2 068 | |||||
Interest expenses, bln rub | 553.0 | 553.0 | 636.0 | 636.0 | 570.0 | |||||
Assets, bln rub | 90 981 | 90 981 | 90 948 | 90 948 | 89 981 | 89 981 | ||||
Net Assets, bln rub | ? | 52 551 | 52 551 | 51 483 | 51 483 | 50 214 | 50 214 | |||
Debt, bln rub | 24 114 | 24 114 | 24 364 | 24 364 | 25 024 | 25 024 | ||||
Cash, bln rub | 10 573 | 10 573 | 7 959 | 7 959 | 8 005 | 8 005 | ||||
Net debt, bln rub | 13 541 | 13 541 | 16 405 | 16 405 | 17 019 | 17 019 | ||||
Ordinary share price, rub | 104.4 | 104.4 | 91.0 | 91.0 | 80.2 | 72.0 | ||||
Number of ordinary shares, mln | 1 342 | 1 342 | 1 330 | 1 330 | 1 322 | |||||
Market cap, bln rub | 140 093 | 140 093 | 120 945 | 120 945 | 0 | 95 206 | ||||
EV, bln rub | ? | 153 634 | 153 634 | 137 350 | 137 350 | 17 019 | 112 225 | |||
Book value, bln rub | -3 546 | -3 546 | -4 786 | -4 786 | 9 228 | -3 997 | ||||
EPS, rub | ? | 3.75 | 3.75 | 2.83 | 2.83 | 2.18 | ||||
FCF/share, rub | 4.45 | 4.45 | 3.44 | 3.44 | 1.77 | |||||
BV/share, rub | -2.64 | -2.64 | -3.60 | -3.60 | -3.02 | |||||
EBITDA margin, % | ? | 27.6% | 28.2% | 29.0% | 29.0% | 25.2% | ||||
Net margin, % | ? | 15.9% | 15.9% | 12.0% | 12.0% | 11.7% | ||||
FCF yield, % | ? | 4.27% | 4.27% | 3.79% | 3.79% | 0.00% | 2.46% | |||
ROE, % | ? | 9.59% | 9.59% | 7.30% | 7.30% | 0.00% | 5.75% | |||
ROA, % | ? | 5.54% | 5.54% | 4.13% | 4.13% | 0.00% | 3.21% | |||
P/E | ? | 27.8 | 27.8 | 32.2 | 32.2 | 33.0 | ||||
P/FCF | 23.4 | 23.4 | 26.4 | 26.4 | 40.7 | |||||
P/S | ? | 4.42 | 4.42 | 3.87 | 3.87 | 3.86 | ||||
P/BV | ? | -39.5 | -39.5 | -25.3 | -25.3 | 0.00 | -23.8 | |||
EV/EBITDA | ? | 17.5 | 17.2 | 15.2 | 15.2 | 18.1 | ||||
Debt/EBITDA | 1.55 | 1.52 | 1.81 | 1.81 | 2.74 | |||||
R&D/CAPEX, % | 200.7% | 200.7% | 184.8% | 184.8% | 256.3% | |||||
CAPEX/Revenue, % | 4.32% | 4.32% | 4.67% | 4.67% | 3.27% | |||||
Medtronic shareholders |